Journal
DRUG DISCOVERY TODAY
Volume 13, Issue 3-4, Pages 124-134Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2007.12.005
Keywords
-
Categories
Funding
- NEI NIH HHS [R21 EY017360-01A1, R24 EY017045-02, R24 EY017045, R21 EY017360] Funding Source: Medline
Ask authors/readers for more resources
The eye is afflicted by chronic vision debilitating neovascular disorders, such as age-related macular degeneration, proliferative diabetic retinopathy, and corneal angiogenesis. Photodynamic therapy (PDT) is an innovative, evolving approach for treating neovascular diseases of the eye. PDT refers to the process of activating a light sensitive agent or carrier with non-thermal light to induce chemical reactions that ameliorate a pathological condition. Key components of PDT include a photosensitizer, a colloidal carrier or formulation and a light source. This article summarizes currently available clinical PDTs, desirable features of PDTs and photosensitizers, useful light sources for PDT and investigational nanosystems, and colloidal carriers for PDT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available